Weekly Fosaprepitant Betters Quality of Life During Chemoradiotherapy

Patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy reported higher quality of life and were less likely to experience vomiting when receiving fosaprepitant every week as opposed to every three weeks.

Related Keywords

China ,United States ,American , ,American Cancer Society ,Sun Yat Sen University ,Sun Yat Sen University Cancer Center ,Drug Administration ,Yat Sen University ,South Asia ,Middle East ,Side Effect Management ,Head And Neck Cancer ,